US Edition
News from Pharmaphorum
If you want to know if Pharmaphorum is credible or reliable, look no further. We rank Pharmaphorum as High factuality. Find out more about our methodology here.
Media Bias Ratings
Average Bias Rating:
Center
Center
byAd Fontes MediaDo you disagree?
Edit bias
Learn more about Media Bias Ratings.
Factuality
Learn more about Factuality Ratings
Reveal Factuality Ratings by upgrading to a Premium account.
Tap Upgrade to explore subscription options to meet all your reading needs.
Ownership
Learn more about Ownership categories
Reveal Ownership Data by upgrading to a Vantage account.
Tap Upgrade to explore subscription options to meet all your reading needs.
Top Pharmaphorum News
FDA · United States(MedPage Today) -- The FDA approved trastuzumab deruxtecan (T-DXd; Enhertu) in combination with pertuzumab (Perjeta) for the first-line treatment of adults with unresectable or metastatic HER2-positive breast cancer.
Approval was based on results...See the Story
AstraZeneca, Daiichi's breast cancer drug gets FDA nod as first-line treatment
80% Center coverage: 10 sources
FDA · United States(MedPage Today) -- Under a program designed to accelerate the approval of products that could address key national priorities, the FDA said it proactively awarded a national priority voucher to teclistamab (Tecvayli) in combination with daratumumab...See the Story
Myeloma Combination Cuts Line for FDA Approval After Strong ASH Results
83% Center coverage: 6 sources
